Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.75 |
| ▸ | PPARA | Q07869 | 7/20 | 0.75 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL7041209 | 0.93 | PPARG (0.70) | PPARGPPARATP53 | |
| Lithium Ion SCHEMBL7037283 | 0.92 | PPARG (0.69) | PPARGPPARATP53MAPT | |
| SCHEMBL7035460 | 0.90 | PPARG (0.62) | PPARGPPARASIRT2TP53MAPT | |
| SCHEMBL7033982 | 0.89 | PPARG (0.61) | PPARGPPARASIRT2TP53MAPT | |
| SCHEMBL7035597 | 0.88 | PPARG (0.59) | PPARGPPARASIRT2TP53MAPT | |
| Lithium Ion SCHEMBL7039962 | 0.86 | PPARG (1.00) | PPARGPPARATP53 | |
| Lithium Ion SCHEMBL7042063 | 0.84 | PPARG (0.69) | PPARGPPARATP53MAPTNPC1 | |
| Lithium Ion SCHEMBL7036028 | 0.84 | PPARG (1.00) | PPARGPPARANPC1RAB9A | |
| Lithium Ion SCHEMBL7034820 | 0.84 | PPARG (1.00) | PPARGPPARATP53NPC1RAB9A | |
| Lithium Ion SCHEMBL7037651 | 0.83 | PPARG (0.75) | PPARGPPARATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885SIRT2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.